According to a May 21 press release from pharmaceutical company Eli Lilly, the weekly injectable weight-loss drug Retatrutide, currently in development, has recorded impressive results in its Phase 3 clinical trials.
This large-scale trial involved 2,339 participants who were obese or overweight. The results showed that Retatrutide was significantly more effective than existing weight-loss medications on the market, helping nearly half of the participants lose more than 30% of their body weight after two years of treatment.
Specifically, when using the highest dose of 12mg, patients can lose an average of up to 30.3% of their body weight after 104 weeks. Even at lower doses, this drug still demonstrates significant weight loss potential, with reductions ranging from 27.9% to 29.5%.
Obese patients can lose an average of up to 30.3% of their body weight after 104 weeks of taking Eli Lilly's Retatrutide. (Image caption: MarketBeat)
What sets Retatrutide apart from other common weight-loss drugs like Zepbound (from Eli Lilly) or Wegovy (from Novo Nordisk) is its multi-targeted mechanism of action. Retatrutide is a triple agonist, capable of simultaneously acting on three receptors: GLP-1, GIP, and glucagon.
This comprehensive mechanism of action not only effectively controls appetite but also promotes vigorous calorie burning in the body. As a result, the medication achieves a stronger effect, making it a particularly suitable solution for cases that do not respond well to conventional GLP-1 support medications.
Commenting on this medical achievement, Dr. Ania Jastreboff, the lead researcher from Yale University (USA), affirmed that this is an extremely impressive result. She emphasized that almost all participants in the trial achieved clinically significant weight loss, and noted a clear improvement in cardiovascular metabolic indicators.
Notably, approximately 65% of patients who received the highest dose of the treatment successfully reduced their body mass index (BMI) to below 30, officially escaping obesity.
Dan Skovronsky, chief scientific officer and product manager at Eli Lilly, further shared that a weight reduction of up to 30% is unprecedented for similar treatments, and this effect is comparable only to gastric bypass surgery.
However, Skovronsky also noted that, depending on individual health goals, not everyone is required to maintain the highest dose for the entire two years.
In terms of safety and side effects, Retatrutide exhibits characteristics similar to other GLP-1 class drugs. Users primarily experience gastrointestinal symptoms such as nausea, diarrhea, and constipation, especially at high doses. A few cases have been reported of upper respiratory tract infections or neurological disturbances.
However, the rate of patients having to discontinue the medication due to side effects was lower in the low-dose groups compared to the placebo control group. At the same time, the company stated that no serious problems related to cardiovascular or liver function had been detected in the patients.
Currently, Eli Lilly has not yet officially submitted an application to the U.S. Food and Drug Administration (FDA) for marketing authorization of Retatrutide. The company is continuing to conduct additional trials and is committed to making every effort to bring this product to those in need at the most reasonable price possible.
Source: https://suckhoedoisong.vn/buoc-tien-dot-pha-giup-giam-toi-30-can-nang-trong-cuoc-chien-chong-beo-phi-16926052217585419.htm
Comment (0)